Last reviewed · How we verify
FLOLAN injection with reformulated diluent
Epoprostenol (prostacyclin) directly relaxes vascular smooth muscle and inhibits platelet aggregation to reduce pulmonary vascular resistance.
Epoprostenol (prostacyclin) directly relaxes vascular smooth muscle and inhibits platelet aggregation to reduce pulmonary vascular resistance. Used for Pulmonary arterial hypertension (PAH), Acute pulmonary hypertension during cardiac surgery.
At a glance
| Generic name | FLOLAN injection with reformulated diluent |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Prostacyclin analog |
| Target | Prostacyclin receptor (IP receptor) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Epoprostenol is a prostacyclin analog that binds to prostacyclin receptors on vascular smooth muscle cells, triggering vasodilation and reducing pulmonary artery pressure. It also inhibits platelet aggregation and has antiinflammatory properties. The reformulated diluent in this product improves stability and ease of preparation for continuous intravenous infusion.
Approved indications
- Pulmonary arterial hypertension (PAH)
- Acute pulmonary hypertension during cardiac surgery
Common side effects
- Flushing
- Headache
- Hypotension
- Jaw pain
- Nausea
- Diarrhea
- Catheter-related infections
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: